Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
BACKGROUND: Thrombotic events are reduced with cangrelor, an intravenous P2Y12 inhibitor. We sought to characterize the timing, number, and type of early events (within 2 hours of randomization) in CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subj...
Main Authors: | Bhatt, D.L (Author), Cavender, M.A (Author), CHAMPION PHOENIX Investigators* (Author), Deliargyris, E.N (Author), Gibson, C.M (Author), Hamm, C.W (Author), Harrington, R.A (Author), Leonardi, S. (Author), Lopes, R.D (Author), Mahaffey, K.W (Author), Prats, J. (Author), Price, M.J (Author), Steg, P.G (Author), Stone, G.W (Author), White, H.D (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION
by: Bhatt, D.L, et al.
Published: (2022) -
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
by: Bhatt, D.L, et al.
Published: (2022) -
Cangrelor Use in Routine Practice: A Two-Center Experience
by: Niels M. R. van der Sangen, et al.
Published: (2021-06-01) -
Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
by: A. Selvarajah, et al.
Published: (2021-06-01) -
The Use of Cangrelor in the Treatment of a Patient with COVID-19-Associated Acute Coronary Syndrome
by: S. V. Salo, et al.
Published: (2021-06-01)